Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jul 14, 2025
Date Accepted: Mar 25, 2026
Protocol: Cross-Sectional Pilot Study Evaluating a Novel Multiplex Near–Point-of-Care PCR Assay for Detecting Sexually Transmitted Infections Among PrEP Users in Western Kenya with an Epidemiological Assessment
ABSTRACT
Background:
The global impact of sexually transmitted infections (STIs) significantly affects low- and middle-income countries (LMICs)In Kenya, where access to STI diagnostics is limited, effective diagnostic solutions are critically needed. The primary aim of this study is to validate the performance of FlashDx STI multiplex assay, in detecting STIs including Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), Mycoplasma Genitalium (MG), Mycoplasma Hominis (MH) and Ureaplasma Species (US) compared to the CE-IVD-D Golden Standard dual rtPCR of Mikrogen (CT and NG).
Objective:
Epidemiological data generated will include prevalence rates for all 6 STIs, providing an overview of STI prevalence with external validation to ensure accuracy and reliability.
Methods:
We propose to conduct a comparative cross-sectional study with up to 400 young PrEP users aged between 15 and 30 at the Kenya Medical Research Institute Center for Microbiology Research Research Care and Training Program research site in Kisumu Kenya. Urine samples will be collected and analyzed using the FlashDx STI multiplex chip-based assay to detect six STIs, with results confirmed by the CE-IVD-D certified Mikrogen assay in the Netherlands.
Results:
It is anticipated that the FlashDx STI multiplex assay will demonstrate high sensitivity and specificity in detecting CT and NG. The study will provide prevalence rates for all six STIs (CT, NG, TV, MG, USP and MH) offering a comprehensive overview of STI prevalence in this high-risk population
Conclusions:
The findings from this study are expected to show the FlashDx STI multiplex assay as an effective POC system for diagnosing six common STIs in settings such as Kenya. By demonstrating its usability, accuracy, and reliability, the FlashDx assay could be considered for broader implementation in clinical settings across Kenya and other LMICs. This could significantly improve STI diagnosis and treatment, ultimately reducing the burden of STIs and their associated complications in these regions. In addition to providing insights into the prevalence of CT and NG, this study will also offer valuable estimates for other STIs relevant to female reproductive health. Clinical Trial: KEMRI Ethical approval registration: KEMRI/SERU/CMR/P00291/5102
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.